Compugen Announces Two New Advancements in Proteomics.Business Editors & Health/Medical Writers BIOWIRE2K SAN FRANCISCO--(BW Healthwire)--June 20, 2001 ProtoCall(TM) Mass Spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. Engine and Z3 Version 2.0 2D-Gel Analysis System Introduced Compugen Ltd. (Nasdaq:CGEN CGEN Convective Sigmet Generation ) announced at the Beyond Genome conference in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden today the availability of two new advancements for proteomics researchers: ProtoCall(TM), a Web-based mass spectrometry protein identification and characterization system, and a new version of Z3 2D-Gel high throughput system for comparative analysis of protein expression. The separation and analysis of complex mixtures of proteins - typically by 2D-Gel analysis - followed by the process of identification and characterization of individual proteins utilizing mass spectrometry, are two key components of current proteomics research. ProtoCall and Z3 2D-Gel version 2.0 significantly enhance research in these two key areas and result from Compugen's continuing efforts to provide the tools and platforms necessary to accelerate life science research and the merger of genomics and proteomics. "The algorithms and database behind this system promise to make ProtoCall a useful tool for proteomics researchers engaged in the identification of proteins by mass spectrometry," said Professor Ruedi Aebersold Rudolf Aebersold (better known as Ruedi Aebersold) is a Swiss biologist, regarded as a pioneer in the fields of proteomics and systems biology. Prof. Aebersold has primarily researched techniques for measuring proteins in complex samples, in many cases via mass spectrometry. , Institute of Systems Biology Systems biology, a field of study in the biosciences, focuses on the systematic study of complex interactions in biological systems. Particularly from 2000 onwards, the term is used widely in the biosciences, and in a variety of contexts. . "ProtoCall offers proteomics researchers a unique opportunity to link their protein data to the relevant genomic and transcriptomic information and by doing so, adds an important dimension in the knowledge they extract from their research," said Dr. Zeev Smilansky, Vice President Proteomics, Compugen. "The system has been in beta testing (programming) beta testing - Testing a pre-release (potentially unreliable) version of a piece of software by making it available to selected users. This term derives from early 1960s terminology for product cycle checkpoints, first used at IBM but later standard throughout the at a number of commercial and academic institutions, and has been enthusiastically received. ProtoCall is a natural complement to our well-respected, innovative Z3 2D-Gel image analysis system." Through the use of novel proprietary algorithms to extract and analyze protein mass spectrometry Protein mass spectrometry refers to the application of mass spectrometry to the study of proteins. Mass spectrometry is an important emerging method for the characterization of proteins. data and then search relevant databases, ProtoCall can provide researchers with meaningful information about the identity and characteristics of proteins. ProtoCall is the only search engine that searches against a comprehensive database of proteins from all public sources as well as from Compugen's proprietary annotated transcriptome The transcriptome is the set of all messenger RNA (mRNA) molecules, or "transcripts", produced in one or a population of cells. The term can be applied to the total set of transcripts in a given organism, or to the specific subset of transcripts present in a particular cell type. , derived from the company's LEADS platform. Compugen's proprietary transcriptome database includes novel predicted human proteins based upon genomic and EST EST electroshock therapy. EST abbr. electroshock therapy (expressed sequence tag An expressed sequence tag or EST is a short sub-sequence of a transcribed spliced nucleotide sequence (either protein-coding or not). They may be used to identify gene transcripts, and are instrumental in gene discovery and gene sequence determination. ) data and encompasses over 70,000 human sequences together with their derived proteins. Fast and easy to use over the Internet, ProtoCall comes with informative detailed reports that facilitate downstream research decision-making. At present, ProtoCall is available at no cost over the Web (http://www.labonweb.com/) and constitutes an additional and important step in an evolving Compugen product line that is directed towards providing integrated solutions for genomic and proteomic research. Additional ProtoCall components and product line extensions Product line Extensions and Patient safety In a world of product line extensions, there are many different products with similar names. Examples of these include oxycodone versus oxycontin (oycodone CR), buproprion vs buprion SR vs bruproprion XL, codeine versus codeine contin will be made available during 2001 on a fee basis. Compugen launched the initial version of Z3 in September 2000 and version 1.5 in February 2001. The core Z3 technology employs advanced proprietary image analysis algorithms to substantially enhance the accuracy and automate the analysis process of 2D-Gel images. The analyzed images use a color overlay technology that displays the results in a quick, easy-to-read format readily visible at first glance. This, together with detailed data tables, allows accurate and efficient identification of the differential protein expression patterns present in test samples as revealed by 2D-Gels, for example comparing the patterns resulting from samples taken from normal and diseased tissues. Z3 continues to gain recognition and acceptance as a leading product for 2D-Gel analysis. In addition to previously announced customers, such as Aventis Pharma, Genentech Inc., Pfizer Inc. and Procter & Gamble, Z3 has recently been purchased by BASF BASF Bar Association of San Francisco (since 1872; San Francisco, California) BASF Badische Anilin und Soda Fabrik (German chemical products company) BASF Builders Association of South Florida , Merck Co., Inc., Pharmacia Corporation, Schering Plough Corporation, Dr. Friedrich Lottspeich of the Max Planck Noun 1. Max Planck - German physicist whose explanation of blackbody radiation in the context of quantized energy emissions initiated quantum theory (1858-1947) Max Karl Ernst Ludwig Planck, Planck Institute for Biochemistry, Professor Julio Celis of the Danish Cancer Institute, Professor Christopher Leaver of Oxford University's Department of Plant Sciences and other leading commercial and academic research organizations. New features in Z3 version 2.0 include a multi-gel workflow for the simultaneous analysis of an entire gel experiment; connectivity to external excision robots; and a new spot detection system that allows for superior accuracy, sensitivity and speed, thereby advancing Z3 even further towards a completely hands-free analysis. About Compugen Compugen (Nasdaq:CGEN) develops and markets platforms, tools and products that accelerate post-genomic research, the advanced study of proteins and protein pathways, and drug target discovery. Compugen's in-house molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller laboratories conduct original genomic and proteomic research and also provide validation for Compugen's methodologies. Products commercialized to date include: LEADS, Gencarta, DNA Chip DNA chip See DNA microarray. Noun 1. DNA chip - a microchip that holds DNA probes that form half of the DNA double helix and can recognize DNA from samples being tested gene chip design, Z3, LabOnWeb.com and Bioccelerators. For additional information, please visit Compugen's Corporate Web Site at www.cgen.com and the Company's Internet research engine for molecular biologists, www.LabOnWeb.com. This press release contains "forward-looking statements." These statements include words like "may," "expects," "believes," and "intends," and describe opinions about future events. These forward-looking statements are subject to risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; the ability to implement technological improvements; the ability of Compugen to obtain and retain customers. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's Registration Statement on Form F-1 filed with the Securities and Exchange Commission. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion